Vericel (VCEL)
(Delayed Data from NSDQ)
$54.00 USD
+3.97 (7.94%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $54.06 +0.06 (0.11%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$54.00 USD
+3.97 (7.94%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $54.06 +0.06 (0.11%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth F Momentum C VGM
Zacks News
Vericel Corporation (VCEL) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Vericel Corporation (VCEL) delivered earnings and revenue surprises of 500% and 0.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Vericel Corporation (VCEL) Surges 16.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Vericel Corporation (VCEL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Vericel Corporation (VCEL) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Vericel Corporation (VCEL) delivered earnings and revenue surprises of -16.67% and 3.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 23.40% and 44.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 25.93% and 24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
How Much Upside is Left in Vericel Corporation (VCEL)? Wall Street Analysts Think 53%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 52.8% in Vericel Corporation (VCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Vericel Corporation (VCEL) delivered earnings and revenue surprises of -46.15% and 3.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Vericel Corporation (VCEL) delivered earnings and revenue surprises of 0% and 6.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Vericel Corporation (VCEL) Q4 Earnings Miss Estimates
by Zacks Equity Research
Vericel Corporation (VCEL) delivered earnings and revenue surprises of -47.06% and 0.24%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Vericel Corporation (VCEL) Q4 Earnings Expected to Decline
by Zacks Equity Research
Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vericel Corporation (VCEL) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Vericel Corporation (VCEL) delivered earnings and revenue surprises of -266.67% and -11.12%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Vericel Corporation (VCEL) Q3 Earnings Expected to Decline
by Zacks Equity Research
Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vericel Corporation (VCEL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Vericel Corporation (VCEL) delivered earnings and revenue surprises of -33.33% and 7.04%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Vericel Corporation (VCEL) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exact Sciences, Vericel Corp, Home Depot, ExxonMobil and Discover Financial Services highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Exact Sciences, Vericel Corp, Home Depot, ExxonMobil and Discover Financial Services highlighted as Zacks Bull and Bear of the Day
Bear of the Day: Vericel (VCEL)
by Kevin Cook
Restoring cartilage in sports medicine and rebuilding skin after severe burns gave this small-cap big upside
Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Vericel Corporation (VCEL) delivered earnings and revenue surprises of -16.67% and 8.24%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Vericel Corporation (VCEL) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vericel Corporation (VCEL) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Vericel Corporation (VCEL) closed at $42.92, marking a -0.26% move from the previous day.
Global Blood (GBT) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Global Blood (GBT) reports a wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates.
Company News for Feb 25, 2021
by Zacks Equity Research
Companies In The News Are: VCEL, LNG, HZNP, PRAH
ACADIA (ACAD) Beats on Q4 Earnings, Misses on Revenues
by Zacks Equity Research
ACADIA's (ACAD) loss narrows in the fourth quarter of 2020 while it misses estimates for revenues. Nuplazid drives year-over-year revenues.
Vericel Corporation (VCEL) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Vericel Corporation (VCEL) delivered earnings and revenue surprises of 19.05% and 0.40%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Blueprint Medicines (BPMC) Q4 Earnings Beat, Revenues In Line
by Zacks Equity Research
Blueprint Medicines' (BPMC) earnings beat estimates in the fourth quarter of 2020 while revenues meet the same. Shares up.
Vericel Corporation (VCEL) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Vericel Corporation (VCEL) closed at $51.15, marking a -0.04% move from the previous day.